Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.74 |
| ▸ | HPGD | P15428 | 9/20 | 0.74 |
| ▸ | MAPT | P10636 | 8/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.74 |
| ▸ | TP53 | P04637 | 7/20 | 0.74 |
| ▸ | MEN1 | O00255 | 6/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.74 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.74 |
| ▸ | BLM | P54132 | 3/20 | 0.74 |
| ▸ | USP2 | O75604 | 2/20 | 0.74 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 9/20 | 0.59 |
| ▸ | NPC1 | O15118 | 8/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.59 |
| ▸ | POLB | P06746 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL678215 | 0.90 | SMN1; SMN2 (0.74) | SMN1; SMN2ALDH1A1HPGDMAPTHSD17B10 | |
| SCHEMBL5989965 | 0.88 | ALDH1A1 (0.60) | SMN1; SMN2ALDH1A1HPGDMAPTHSD17B10 | |
| 5,7-Dihydroxyisoflavone SCHEMBL1586459 | 0.85 | MEN1 (1.00) | SMN1; SMN2ALDH1A1HPGDMAPTHSD17B10 | |
| SCHEMBL6266319 | 0.85 | ALDH1A1 (0.57) | SMN1; SMN2ALDH1A1HPGDMAPTHSD17B10 | |
| SCHEMBL9755698 | 0.84 | ALDH1A1 (0.56) | SMN1; SMN2ALDH1A1HPGDMAPTHSD17B10 | |
| SCHEMBL12238015 | 0.84 | SMN1; SMN2 (0.79) | SMN1; SMN2ALDH1A1HPGDMAPTHSD17B10 | |
| SCHEMBL10623004 | 0.83 | SMN1; SMN2 (0.94) | SMN1; SMN2ALDH1A1HPGDMAPTHSD17B10 | |
| SCHEMBL12238014 | 0.81 | RAB9A (0.79) | SMN1; SMN2ALDH1A1HPGDMAPTHSD17B10 | |
| SCHEMBL31186354 | 0.81 | SMN1; SMN2 (0.76) | SMN1; SMN2ALDH1A1HPGDMAPTHSD17B10 | |
| SCHEMBL1227819 | 0.81 | SMN1; SMN2 (0.76) | SMN1; SMN2ALDH1A1HPGDMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0248420-B1 | BENZOPYRAN DERIVATIVES | DAIICHI SEIYAKU CO., LTD. (JP) | 1991-09-18 | — | — | EP | claimed |
| CN-116162636-A | Isopentenyl transferase gene PcPT11 and encoding product and application thereof | 中国医学科学院药用植物研究所 | 2023-05-26 | — | — | CN | disclosed |
| CN-103030619-B | C-crystal-form 5-methyl-7-methoxyiso-flavone and preparation method, pharmaceutical compositions and application of C-crystal-form 5-methyl-7-methoxyiso-flavone | INST MATERIA MEDICA CAMS | 2015-04-22 | — | — | CN | disclosed |
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| CN-101591324-B | Three crystal forms of 5-methyl-7-methoxyisoflavone, preparation method thereof, pharmaceutical composition thereof and application thereof | INST MATERIA MEDICA CAMS | 2013-07-10 | — | — | CN | disclosed |
| CN-103030619-A | C-crystal-form 5-methyl-7-methoxyiso-flavone and preparation method, pharmaceutical compositions and application of C-crystal-form 5-methyl-7-methoxyiso-flavone | INST MATERIA MEDICA CAMS | 2013-04-10 | — | — | CN | disclosed |
| CN-101591324-A | Three crystal forms of 5-methyl-7-methoxyisoflavone, preparation method thereof, pharmaceutical composition thereof and application thereof | INST MATERIA MEDICA CAMS (CN) | 2009-12-02 | — | — | CN | disclosed |
| CN-101591225-A | The synthetic method of 5-alkyl resorcinol | UNIV EAST CHINA SCIENCE & TECH (CN) | 2009-12-02 | — | — | CN | disclosed |
| US-7625943-B2 | 5-alkyl-7-alkylcarbonate-isoflavone ester and related method | ROBERTS WILLIAM J | 2009-12-01 | — | — | US | disclosed |
| US-20050065354-A1 | 5-alkyl-7-alkylcarbonate-isoflavone ester and related method | ROBERTS WILLIAM J (US) | 2005-03-24 | — | — | US | disclosed |
| US-6818668-B2 | ADMINISTERING PRODRUGS OF METABOLITES SUCH AS 5-METHYL-7-ETHYL CARBONATE-ISOFLAVONE, TO INCREASING CONCENTRATION OF FLAVONOIDS | BIOTEST LABORATORIES, LLC | 2004-11-16 | — | — | US | disclosed |
| WO-2003087083-A1 | 5-ALKYL-7-ALKYLCARBONATE-ISOFLAVONE ESTER AS ISOFLAVONE PRODRUG | BIOTEST LABORATORIES, LLC (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030195245-A1 | 5-alkyl-7-alkylcarbonate-isoflavone ester and related method | BIOTEST LABORATORIES, LLC | 2003-10-16 | — | — | US | disclosed |
| US-4163746-A | ANABOLIC, 5-METHYL-7-ALKOXYISOFLAVONES | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1979-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | SMN1; SMN2 4749/4885ALDH1A1 1004/4885HPGD 1271/4885 |
| US-20030195245-A1 | 5-alkyl-7-alkylcarbonate-isoflavone ester and related method | CYP2A7, CYP8B1, CYP3A7 | SMN1; SMN2 2349/4885ALDH1A1 708/4885HPGD 223/4885 |
| US-20050065354-A1 | 5-alkyl-7-alkylcarbonate-isoflavone ester and related method | CYP2A7, CYP8B1, CYP3A7 | SMN1; SMN2 2299/4885ALDH1A1 696/4885HPGD 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.